# Symptoms and Stages of Hereditary ATTR Amyloidosis
Hereditary ATTR amyloidosis progresses in stages, but the pattern and speed differ greatly from person to person and by mutation type. Some people have few or no symptoms for years, while others experience rapidly worsening symptoms. Below we describe the main stages and their characteristics.
Stage 1: Asymptomatic Carriers
In this stage, people carry a mutated TTR gene but do not yet have noticeable disease symptoms. They feel healthy and their daily life is not limited. This stage can last years or even decades — some people never develop symptoms, especially with certain mutations that manifest late.
Because hereditary ATTR amyloidosis is hereditary, carriers are often discovered after genetic screening in families where someone has previously been diagnosed. Asymptomatic carriers can decide whether to have regular check-ups (with heart ultrasound, nerve tests or blood tests), but this is entirely a matter for discussion with their doctor.
**Duration and Particulars:**
No fixed data on how long this stage lasts on average — this depends heavily on the mutation, genetic background and individual factors. Some studies show that acoramidis (a disease-modifying drug) can be used in very early stages in asymptomatic carriers with specific mutations, but this is still the subject of clinical trials and public debate.
Stage 2: Early Symptomatic Phase
In this phase, the first noticeable symptoms appear. The pattern depends on which form of hereditary ATTR you have:
**In the neuropathic type (ATTR-PN):**
- Tingling and numbness in feet and lower legs (usually the first sign)
- Feeling of "burning" in feet
- Numbness that gradually creeps upward
- Balance problems or unsteadiness
- Loss of strength in legs, later in arms
- Pain, sometimes radiating
- Tremor (shaking) may occur
These symptoms limit daily functioning — people have difficulty with fine motor skills, walk more carefully because of tripping hazard, and may have problems with work requiring balance or tactile sensitivity.
**In the cardiac type (ATTR-CM):**
- Shortness of breath, especially during exertion
- Fatigue
- Irregular heartbeat or heart palpitations
- Swelling of ankles or legs
- Poor fluid intake
- In some cases fainting or dizziness
Cardiac symptoms quickly limit physical exertion — climbing stairs, running hard or heavy housework become more difficult.
**In the central nervous system type (central ATTR, very rare):**
- Headache
- Confusion or memory problems
- Balance disorders
- In a few reported cases progressive neurological decline
**Duration and Survival:**
This varies greatly. In neuropathic ATTR, the early phase can last months to years before severe limitation occurs. In cardiac ATTR, progression is often faster. Population data show that asymptomatic carriers of certain cardiac mutations (for example Val122Ile) sometimes remain stable for decades. For neuropathic forms: median diagnostic age for many mutations is around 40-50 years, but early-onset mutations (for example V30M) can show symptoms around the 20th-30th year — no uniform figure available.
Survival rates are difficult to give without specifying mutation and organ involvement. These are population averages that tell you nothing about one individual.
Stage 3: Progressive Phase with Moderate to Severe Limitations
In this stage, symptoms become clearer and daily life becomes noticeably more difficult.
**Neuropathic Progression:**
- Tactile sensitivity decreases further; lower limbs feel "dead" or "numb"
- Loss of strength increases; some people need help walking
- Autonomic symptoms appear: impotence, urinary problems, bowel problems, stomach problems (delayed gastric emptying)
- Fall risk increases significantly
- Weight loss may occur due to stomach problems
- Sleep disturbance
Daily life requires adjustments: mobility aids, adapted home arrangements, greater dependence on others.
**Cardiac progression:**
- Increasing shortness of breath even at rest
- Severe activity limitation (only light activities possible)
- Fluid accumulation may increase despite treatment
- Arrhythmias may become more frequent
- Kidney function may deteriorate due to low cardiac output
**Combined forms:**
Many patients have both nerve involvement and heart involvement, which increases complexity.
**Duration and Survival:**
Without treatment, progression in cardiac ATTR is often faster. Historical data suggest median survival of a few years after diagnosis (3-7 years depending on the source and study period), but with modern disease-modifying therapies this improves significantly — exact figures are subject to recent studies (2026). In neuropathic forms without cardiac involvement, progression can continue for decades, but severe disability may develop. These are population averages; individual courses vary widely.
Phase 4: Advanced phase with severe multi-system involvement
If untreated or with insufficient response to therapy, hereditary ATTR can expand to involve multiple organ systems at once.
**Possible complications:**
- Severe polyneuropathy: many patients are immobile or dependent on a wheelchair
- Heart failure: significant fluid accumulation, extreme shortness of breath, reduced cardiac function
- Gastrointestinal system: severe malnutrition, diarrhea or obstruction
- Autonomic dysfunction: severe low blood pressure, syncope (fainting), urinary urgency day and night
- Kidney failure: sometimes as a direct complication
- In rare central ATTR: progressive neurological deterioration with deafness, ataxia (movement coordination disorders)
- Secondary problems: infections, falls with injuries, social isolation
Daily life is highly dependent on care; many patients need round-the-clock support.
**Survival:**
Without treatment, survival is significantly reduced, especially with cardiac involvement. Historical data suggest median survival of 1-3 years in advanced cardiac ATTR without therapy. With modern disease-modifying medications, these figures are shifting — exact new numbers are limited available, but studies from 2025-2026 show stabilization and even cautious improvement in responders. These are population averages; much depends on when treatment starts, which variant you have, and how you respond to therapy.
Disease progression by organ form: summary
**ATTR neuropathy (ATTR-PN):**
Often gradual progression over months to years. Many patients survive, but may become severely disabled. With treatment, symptoms can stabilize or even improve.
**ATTR cardiomyopathy (ATTR-CM):**
Progression can be faster, especially without treatment. Heart failure and arrhythmias are serious complications. With modern therapies (tafamidis, vutisiran, inotersen and others), stabilization or remission is achieved more often. Survival rates are improving.
**Central / neural ATTR (rare):**
Course highly variable and understudied. Some reported cases show progression over years with possibly good response to therapy.
**Combined forms:**
Many patients have both neuropathy and cardiac involvement. This makes prognosis more complex and requires multidisciplinary care.
When to contact your healthcare provider?
It is advisable to consult your doctor if:
- **New or worsening tingling, numbness or weakness** in hands or feet
- **New or worsening shortness of breath,** especially at rest
- **Irregular heartbeat** or heart palpitations that persist
- **Swelling of feet, legs or abdomen**
- **Severe fatigue** that hinders daily functioning
- **Gastrointestinal problems:** persistent diarrhea, constipation, nausea or vomiting
- **Involuntary weight loss**
- **Fainting or severe dizziness**
- **Great difficulty with balance or falls**
- **Pain that does not disappear with normal remedies**
Your healthcare provider can assess whether adjustments in care or therapy are needed.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._